Silk Road Medical, Inc (SILK) Stock Analysis

Silk Road Medical, Inc (SILK) Healthcare & Pipeline Overview

Silk Road Medical, Inc. specializes in innovative medical devices for carotid artery disease treatment, primarily through its ENROUTE Transcarotid Neuroprotection System. With a focus on improving patient outcomes via transcarotid artery revascularization (TCAR), the company operates in the competitive medical device industry, holding a significant position in the neurovascular space.

What Is the Investment Thesis for SILK?

Silk Road Medical presents an investment opportunity centered on its innovative TCAR technology and its potential to become the standard of care for carotid artery disease treatment. The company's ENROUTE system addresses a critical need for safer and more effective stroke prevention during carotid revascularization. Key value drivers include continued adoption of TCAR by vascular surgeons, expansion into new geographic markets, and positive long-term clinical outcomes data supporting the superiority of TCAR over traditional methods. With a gross margin of 71.7%, there is potential for profitability as the company scales. However, the negative profit margin of -31.5% indicates the company is not yet profitable. Upcoming catalysts include ongoing clinical trials and potential expansion of TCAR indications. Potential risks include competition from established medical device companies and the pace of adoption of TCAR by the medical community.

Based on FMP financials and quantitative analysis

SILK Key Highlights

Market capitalization of $1.12B reflects investor confidence in Silk Road Medical's growth potential.

• Gross margin of 71.7% demonstrates the company's ability to maintain high profitability on its products.
• Operating in the medical device industry, Silk Road Medical is positioned to benefit from the aging population and increasing prevalence of carotid artery disease.
• The ENROUTE Transcarotid Neuroprotection System is a key differentiator, offering a unique approach to stroke prevention during carotid revascularization.
• The company's focus on transcarotid artery revascularization (TCAR) aligns with the trend toward minimally invasive surgical procedures.

Who Are SILK's Competitors?

SILK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are SILK's Key Strengths?

Innovative TCAR technology with potential to become the standard of care.

• Strong clinical data supporting the safety and efficacy of the ENROUTE system.
• Experienced management team with a proven track record in the medical device industry.
• High gross margin of 71.7%.

What Are SILK's Weaknesses?

Negative profit margin of -31.5% indicates the company is not yet profitable.

• Reliance on a single product line (ENROUTE system).
• Limited geographic reach, primarily focused on the United States.
• Relatively small size compared to larger medical device companies.

What Could Drive SILK Stock Higher?

SILK catalyst: Publication of long-term clinical outcomes data for the ENROUTE system, potentially demonstrating superior outcomes compared to traditional methods.

• Increasing adoption of TCAR by vascular surgeons as they become more familiar with the procedure and its benefits.
• Expansion of TCAR indications to include more complex carotid artery disease cases.

What Are the Key Risks for SILK?

Negative return on equity (-35.4%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $9.7M recently.
• Competition from established medical device companies with greater resources and broader product portfolios.
• Slower-than-expected adoption of TCAR by the medical community due to concerns about cost or complexity.
• Unfavorable changes in reimbursement policies that could reduce the profitability of TCAR procedures.
• Product liability claims related to the use of the ENROUTE system.

What Are the Growth Opportunities for SILK?

• Expansion into new geographic markets represents a significant growth opportunity for Silk Road Medical. While the company's primary focus has been the United States, there is potential to expand into Europe and Asia, where the prevalence of carotid artery disease is also high. The timeline for international expansion is dependent on regulatory approvals and establishing distribution networks, but could contribute significantly to revenue growth within the next 3-5 years. The global market for carotid artery disease treatment is estimated to be worth billions of dollars, providing ample opportunity for Silk Road Medical to increase its market share.
• Increasing adoption of TCAR by vascular surgeons is a key growth driver for Silk Road Medical. As more surgeons become trained and comfortable with the TCAR procedure, the demand for the ENROUTE system is expected to increase. The company can accelerate adoption by providing comprehensive training programs, clinical support, and ongoing research to demonstrate the benefits of TCAR over traditional methods. The timeline for increased adoption is dependent on surgeon education and awareness, but could lead to significant revenue growth within the next 2-3 years. The market for carotid artery stenting is estimated to be worth hundreds of millions of dollars, providing a substantial opportunity for Silk Road Medical to capture a larger share.
• Positive long-term clinical outcomes data supporting the superiority of TCAR over traditional methods could drive significant growth for Silk Road Medical. As more data becomes available demonstrating the safety and efficacy of TCAR, physicians are more likely to adopt the procedure. The company can generate this data through ongoing clinical trials and post-market surveillance studies. The timeline for generating and publishing this data is dependent on the duration of the studies, but could have a significant impact on adoption within the next 3-5 years. The potential market for TCAR is significant, as it could become the standard of care for carotid artery disease treatment.
• Expanding the indications for TCAR beyond the current approved uses could open up new growth opportunities for Silk Road Medical. The company is exploring the use of TCAR in patients with more complex carotid artery disease, such as those with tortuous anatomy or challenging lesions. Expanding the indications would require additional clinical trials and regulatory approvals, but could significantly increase the potential market for TCAR. The timeline for expanding indications is dependent on the progress of clinical trials and regulatory review, but could contribute to revenue growth within the next 3-5 years. The potential market for expanded TCAR indications is substantial, as it could address a wider range of patients with carotid artery disease.
• Development of next-generation TCAR technology represents a long-term growth opportunity for Silk Road Medical. The company is investing in research and development to improve the ENROUTE system and develop new devices for carotid artery disease treatment. Next-generation technology could include improved stent designs, enhanced neuroprotection systems, and more user-friendly delivery systems. The timeline for developing and commercializing next-generation technology is dependent on the progress of research and development, but could contribute to revenue growth within the next 5-10 years. The potential market for next-generation TCAR technology is significant, as it could further improve the safety and efficacy of carotid artery disease treatment.

What Are SILK's Competitive Advantages?

• Proprietary TCAR technology with patent protection.
• First-mover advantage in the transcarotid artery revascularization market.
• Strong clinical data supporting the safety and efficacy of the ENROUTE system.
• Established relationships with key opinion leaders in the vascular surgery community.

What Does SILK Do?

Silk Road Medical, Inc., founded in 2007 and headquartered in Sunnyvale, California, is a medical device company dedicated to developing and marketing innovative solutions for the treatment of carotid artery disease. The company's primary focus is on transcarotid artery revascularization (TCAR), a minimally invasive procedure designed to reduce the risk of stroke during carotid artery stenting. Their flagship product, the ENROUTE Transcarotid Neuroprotection System, is at the core of their offering. This system allows surgeons to directly access the common carotid artery and temporarily reverse blood flow to prevent plaque from dislodging and traveling to the brain during the procedure. In addition to the ENROUTE system, Silk Road Medical offers the ENROUTE Transcarotid Stent System, a self-expanding stent designed for optimal vessel conformability and scaffolding. They also provide the ENHANCE Transcarotid Peripheral Access Kit, which facilitates initial access to the common carotid artery, and the ENROUTE 0.014 Guidewire, used for navigating and crossing target lesions during interventional procedures. Silk Road Medical's products are primarily sold in the United States, targeting vascular surgeons, interventional cardiologists, and interventional radiologists who perform carotid artery procedures. The company's commitment to innovation and patient safety has established it as a key player in the carotid artery disease treatment market.

What Products and Services Does SILK Offer?

• Develop and market the ENROUTE Transcarotid Neuroprotection System for carotid artery disease treatment.
• Offer a minimally invasive approach to carotid revascularization called transcarotid artery revascularization (TCAR).
• Provide the ENROUTE Transcarotid Stent System, a self-expanding stent designed for carotid artery stenting.
• Offer the ENHANCE Transcarotid Peripheral Access Kit for gaining access to the common carotid artery.
• Manufacture and distribute the ENROUTE 0.014 Guidewire for navigating and crossing target lesions.
• Focus on reducing the risk of stroke during carotid artery procedures through innovative medical devices.
• Provide training and support to vascular surgeons, interventional cardiologists, and interventional radiologists on the use of their products.

How Does SILK Make Money?

• Silk Road Medical generates revenue primarily through the sale of its ENROUTE Transcarotid Neuroprotection System and related products.
• The company sells its products directly to hospitals and clinics, as well as through distributors.
• Silk Road Medical focuses on providing comprehensive training and support to physicians to ensure proper use of its products.

What Industry Does SILK Operate In?

Silk Road Medical operates within the medical device industry, specifically targeting the neurovascular market. The industry is characterized by technological innovation, stringent regulatory requirements, and intense competition. The carotid artery disease treatment market is driven by the aging population and the increasing prevalence of atherosclerosis. Silk Road Medical's TCAR technology competes with traditional carotid endarterectomy (CEA) and transfemoral carotid artery stenting (TF-CAS). The company's focus on minimizing stroke risk during carotid procedures positions it favorably in a market that increasingly values patient safety and improved outcomes.

Who Are SILK's Key Customers?

• Vascular surgeons who perform carotid artery procedures.
• Interventional cardiologists who treat carotid artery disease.
• Interventional radiologists who perform carotid artery stenting.
• Hospitals and clinics that offer carotid artery disease treatment.

Silk Road Medical, Inc (SILK) Valuation Context

Valued at $1.12B, SILK is classified as a small-cap stock.

SILK Revenue & Earnings Trend

In Jun 2024, SILK generated $51.2M in top-line revenue, marking a sequential increase of 5.7%. The company recorded a net loss of $16.6M, with diluted EPS of $-0.42.

Company Profile

Silk Road Medical, Inc operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Sunnyvale, US. The company is led by CEO Charles S. McKhann. SILK has traded publicly since 2019.

Return on equity for Silk Road Medical, Inc stands at -35.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -21.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.95 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.2%, the inverse of the P/E and a quick read on earnings relative to price.

Silk Road Medical, Inc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.62 places it in the safe zone, indicating low near-term bankruptcy risk.

Silk Road Medical, Inc has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 8.4% above estimates on average.

Wall Street analysts project Silk Road Medical, Inc revenue of about $244.3M for fiscal 2026, with EPS near $-1.21. The estimate reflects 4 contributing analysts.

The most recent 12 insider filings for Silk Road Medical, Inc break down as 12 sales and 0 purchases. On net that is roughly 527K shares disposed (about $9.7M), a signal worth weighing alongside the fundamentals.

SILK Financials

SILK Latest News

What Investors Ask About Silk Road Medical, Inc (SILK) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources